Assessment of Immunity Induced in Mice by Glycoproteins Derived from Different Strains and Species of Leishmania

Memorias do Instituto Oswaldo Cruz

Volumn 91, Issue 1, 1996, Pages 63-70

  Pinto Dabés Guimarães, Tânia Mara ^a   Coelho Peixoto De Toledo, Vicente De Paulo ^b   Da Costa, Carlos Alberto ^a   Da Costa, Roberto Teodoro ^a   Genaro, Odair ^a   Williams, Paul ^a   Mayrink, Wilson ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Departamento de Pesquisas   (Brazil)

Author keywords

Glycoproteins; Leishmania; Monoclonal antibodies

Indexed keywords

ANIMALIA; LEISHMANIA AMAZONENSIS;

GLYCOPROTEIN; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; COMPARATIVE STUDY; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; LEISHMANIA; LEISHMANIASIS; METHODOLOGY; MOUSE; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLYCOPROTEINS; IMMUNIZATION; LEISHMANIA; LEISHMANIASIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 0029686306     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0074-02761996000100010     Document Type: Article

References (47)

1. Antunes CMF, Mayrink W, Magalhães PA, Costa CA da, Melo MN, Dias M, Michalick MSM, Williams P, Oliveira-Lima A, Vieira JBF, Schettini APM 1986. Controlled field trial against New World Cutaneous Leishmaniasis. Int J Epidemiol 15: 572-580.
2. Burns Jr JM, Scott JM, Carvalho EM, Russo DM, March CJ, Van Ness KP, Reed SG 1991. Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses. J Immunol 146: 742-748.
3. Button LL, Reiner NE, McMaster WR 1991. Modification of Leishmania GP63 genes by the polymerase chain reaction for expression of nonfusion protein at high levels of Escherichia coli: application to mapping protective T cell determinants. Mol Biochem Parasitol 44: 213-216.
4. Camargo ME 1966. Fluorescent antibody for the serodiagnosis of American Trypanosomiasis. Technical modification employing preserved culture forms of Trypanosoma cruzi in a slide test. Rev Inst Med Trop São Paulo 8: 227-234.
5. Champsi J, McMahon-Pratt 1988. Membrane Glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 52: 3272-3279.
6. Chang CS, Chang KP 1986. Monoclonal antibody affinity purification of a Leishmania membrane glycoprotein and its inhibition of Leishmania-macrophage binding. Proc Natl Acad Sci USA 83: 100-104.
7. Chaudhuri G, Chang KP 1988. Acid protease activity of a major surface membrane glycoprotein (GP63) from Leishmania mexicana promastigotes. Mol Biochem Parasitol 27: 43-52.
8. Chaudhuri G, Chaudhuri M, Pan A, Chang KP 1989. Surface acid proteinase (GP63) of Leishmania mexicana. J Biol Chem 264: 7483-7489.
9. Convit J, Pinardi ME, Rondon AJ 1972. Diffuse cutaneous leishmaniasis: A disease due to an immunological defect of the host. Trans R Soc Trop Med Hyg 66: 603-610.
10. Costa CA da 1986. Infecção experimental do camundongo isogênico C57BL/10 com Leishmania mexicana amazonensis, estudos da atividade imunogênica de uma vacina com promastigotas mortas. PhD Thesis. Universidade Federal de Minas Gerais, Belo Horizonte, 168 pp.
11. Costa CA da, Afonso LCC, Tavares CAP, Nascimento E, Dabés TMP, Mayrink W 1990. Protective antigens isolated from a vaccine against cutaneous leishmaniasis. p. 28-29 Meeting on vaccines against leishmaniasis. UFMG-ICB, Belo Horizonte..
12. Costa CA da, Afonso LCC, Toledo VPCP, Nascimento E, Tavares CAP, Mayrink W 1992. Evaluation of an industrialized non living promastigote vaccine against cutaneous leishmaniasis. Parassitologia 34: 45-51.
13. Costa CA da, Nascimento E, Dabés TMP, Afonso LCC, Taboada DC, Santos Lima M, Tavares CAP, Michalick MSM, Melo MN, Dias M, Costa RT da, Mayrink W 1988. Vacinação de camundongos com antígeno de Leishmania purificado por anticorpos monoclonais. III Reunião Anual da Federação das Sociedades de Biologia Experimental, Caxambu, 385 pp.
14. Engvall E 1980. Enzyme Immunoassay ELISA and Emit. Methods Enzimol 70: 419-423.
15. Erlanger BF, Kokowsky N, Cohen W 1961. The preparation and properties of two new chromogenic substrates of trypsin. Arch Biochem Biophys 95: 271-278.
16. Etges R, Bouvier J, Bouvier C 1986. The major surface protein of Leishmania promastigotes is a protease. J Biol Chem 261: 9098-9101.
17. Etges R, Bouvier J, Hoffman R, Bordier C 1985. Evidence that the major surface protein of three Leishmania species are structurally related. Mol Biochem Parasitol 14: 141-149.
18. Garrido RB 1983. Leishmanias by leishmaniasis tegumentaria on America Latina. Bol Of Sanit Panam 95: 418-426.
19. Galfré G, Milstein C 1981. Preparation of monoclonal antibodies: strategies and procedures. Meth Enzymol 73: 3-46.
20. Guimarães TMPD, Toledo VPCP, França-Silva JC, Hermeto MV, Genaro O, Costa RT, Nascimento E, Tavares CAP, Mayrink W 1992. Vaccination of dogs and mice against cutaneous Leishmaniasis with purified antigens of Leishmania. (Leishmania) amazonensis. Mem Inst Oswaldo Cruz 87(Suppl. II): 59.
21. Handman E, Hocking RE 1982. Stage-specific, strain-specific, and cross-reactive antigens of Leishmania species identified by monoclonal antibodies. Infect Immun 37: 28-33.
22. Jardim A, Alexander J, Teh SH, Ou D, Olafson RW 1990. Immunoprotective Leishmania major synthetic T cell epitopes. J Exp Med 172: 645-650
23. Laemmli UK 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 27: 680-685.
24. Lepay DA, Nogueira N, Cohn Z 1983. Surface antigens of Leishmania donovani promastigotes. J Exp Med 157: 1562-1572.
25. Lohman HL, Langer PJ, McMahon-Pratt D 1990. Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/ M2 of Leishmania amazonensis. Proc Natl Acad Sci USA 87: 8393-8397.
26. Lowry OH, Rosebrough NJ, Farr AL, Raudall RJ 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
27. Marsden PD 1985. Pentavalent antimonials: Old drugs for new diseases. Rev Soc Bras Med Trop 18: 187-198.
28. Mayrink W, Costa CA da, Magalhães PA, Melo MN, Dias M, Michalick MSM, Williams P 1979. A field trial of a vaccine against American Dermal Leishmaniasis. Trans R Soc Trop Med Hyg 73: 385-387.
29. Mayrink W, Magalhães PA, Dias M, Costa CA da, Melo MN, Oliveira-Lima A 1978. Response to Montenegro antigen after immunization with killed Leishmania promastigotes. Trans R Soc Trop Med Hyg 72: 676-679.
30. Mayrink W, Williams P, Costa CA da, Magalhães PA, Melo MN, Dias M, Oliveira Lima A, Michalick MSM, Carvalho EF, Barros GC, Sessa PA, Alencar JTA 1985. An experimental vaccine against American dermal leishmaniasis: experience in the state of Espírito Santo, Brasil. Ann Trop Med Parasit 79: 259-269.
31. Melo MN, Mayrink W, Costa CA da, Magalhães PA, Dias M, Williams P, Araújo FG, Coelho MV, Batista SM 1977. Padronização do antígeno de Montenegro. Rev Inst Med Trop São Paulo 19: 161-164.
32. Mendonça SC, Coutinho SG, Amendoeira RR, Marzochi MCA, Pirmez C 1986. Human American cutaneous leishmaniasts (L. b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol 64: 269-276.
33. Mendonça SCF, de Luca PM, Mayrink W, da Cruz AM, Conceição-Silva F, Restom T, Costa CA, Genaro O, Oliveira MP, Coutinho SG 1993. Characterization of the cell mediated immune responses induced by a vaccine against American tegumentary leishmaniasis in humans. Mem Inst Oswaldo Cruz 88, (Suppl.): 46.
34. Mitchell GF 1984. Host-protective immunity and its suppression in a parasitic disease: murine cutaneous leishmaniasis. Immunol Today 5: 221-223.
35. Modabber F 1989. Experiences with vaccines against cutaneous leishmaniasis of men and mice. Parasitology 98: 549-560.
36. Nascimento E, Mayrink W, Costa CA da, Michalick MSM, Melo MN, Barros GC, Dias M, Antunes CMF, Lima MS, Taboada DC, Liu TY 1990. Vaccination of humans against cutaneous leishmaniasis: Cellular and humoral immune responses. Infect Immun 58: 2198-2203.
37. Pessoa SB, Pestana BR 1940. Ensaio sobre a vacinação preventiva na leishmaniose tegumentar americana com leptomonas mortas. Rev Biol Hig 10: 112-118.
38. Russel DG, Alexander J 1988. Effective immunization against cutaneous leishmaniasis with defined membrane-antigens reconstituted into liposomes. J Immunol 140: 1274-1277
39. Russel DG, Wihelm H 1986. The involvement of the major surface glycoprotein (GP63) of Leishmania promastigotes in the attachment to macrophages. J Immunol 136: 2613-2627.
40. Russo DM, Burns Jr JM, Carvalho EM, Armitage RJ, Grabstein KH, Button LL, McMaster WR, Reed SG 1991. Human T cell responses to GP63, a surface antigen of Leishmania. J Immunol 147: 3575-3580.
41. Russo DM, Jardim A, Carvalho EM, Sleath PR, Armitage RJ, Olafson RW, Reed SG 1993. Mapping human T cell epitopes in Leishmania GP63. Identification of cross-reactive and species-specific epitopes. J Immunol 150: 932-939.
42. Scott P, Pearce E, Natovitz P, Sher A 1987. Vaccination against cutaneous leishmaniasis in a murine model: I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol 139: 221-227.
43. Steinkrauss H, Langer PJ 1992. The protein sequence predicted from a Leishmania guyanensis gp63 major surface glycoprotein gene is divergent as compared with other Leishmania species. Molec Biochem Parasit 52: 141-144.
44. Tavares CAP, Costa CA da, Afonso LCC, Nascimento E, Guimarães TMPD, Melo MN, Michalick MSM, Mares-Guia ML, Mayrink W 1990. Identification, characterization and isolation of antigens from a vaccine against New World Cutaneous Leishmaniasis. p. 74. Meeting on vaccines against leishmaniasis, UFMG-ICB, Belo Horizonte.
45. Yang DM, Rogers MV, Liew FY 1991. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (GP63) from Leishmania major. Immunology 72: 3-9.
46. WHO/UNDP/World Bank 1980. Special programme for research and training in tropical disease, p. 173-191. Fourth Annual Report.
47. Wray W, Boulikas T, Wray VP, Hancock R 1961. Silver Staining of Proteins in Polyacrylamide Gels. Analyt Biochem 118: 197-203.